E.M. POKROVSKAYA², N.A. VOLOV², I.S. VASILYEVA², I.G. GORDEYEV¹, E.P. PAVLIKOVA²

¹Russian National Research Medical University named after N.I. Pirogov, 1 Ostrovityanova St., Moscow, Russian Federation, 117997

²Municipal Clinical Hospital № 15 named after O.M. Filatov, 23 Vishnyakovskaya St., Moscow, Russian Federation, 111539

Pokrovskaya E.M. — Cand. Med. Sc.

Volov N.A. — Cand. Med. Sc., Associate Professor, Department of Hospital Therapy № 1

Vasilyeva I.S. —

Gordeyev I.G. — D. Med. Sc., Professor, Head of the Department of Hospital Therapy № 1

Pavlikova E.P. — D. Med. Sc., Professor

The chronic heart failure (CHF) is the main cause of disability and mortality after myocardial infarction. The drugs active at metabolic level are a promising direction of the CHF pharmacotherapy development. One of such drugs is taurine – the final product of metabolism of sulfur-containing amino acids. The research comprised 40 patients after myocardial infarction with the left ventricular ejection fraction of less than 45% and CHF II–III FK by NYHA classification. The patients were divided into two groups. The basic group included 20 patients who in addition to the standard CHF therapy received taurine (Dibikor, 750 mg/day). The standard CHF therapy was applied to 20 patients of the control group. The groups were comparable by the main clinical-anamnestic characteristics. The treatment duration was 3 months. The influence of taurine on clinical course, left ventricular myocardial contractility, occurrence of heart rhythm disorders, dispersion of QT interval were checked in patients with heart failure after postinfarction cardiosclerosis before treatment and after 3 months. The obtained results prove that taurine should be included into the complex treatment of patients with CHF of II and III FK by NYHA classification after myocardial infarction.

Key words: chronic heart failure, taurine, left ventricular myocardial contractility, dispersion of QT interval, heart rhythm disorders.